Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 9

Results For "clinical-oncology"

86 News Found

Sumitomo Dainippon Pharma Oncology appoints Jatin J. Shah as Chief Medical Officer
People | February 23, 2022

Sumitomo Dainippon Pharma Oncology appoints Jatin J. Shah as Chief Medical Officer

Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline


Lynparza plus abiraterone effective in standard-of-care in 1st-line metastatic castration-resistant prostate cancer
Biotech | February 15, 2022

Lynparza plus abiraterone effective in standard-of-care in 1st-line metastatic castration-resistant prostate cancer

These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium


Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tract cancer
Biotech | January 19, 2022

Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tract cancer

These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium


Bristol Myers neoadjuvant Opdivo (nivolumab) plus chemotherapy assists cancer patients effectively
Biotech | November 09, 2021

Bristol Myers neoadjuvant Opdivo (nivolumab) plus chemotherapy assists cancer patients effectively

Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma


Novartis receives priority review by U.S. FDA and filing acceptance by EMA for Kymriah
Biotech | October 28, 2021

Novartis receives priority review by U.S. FDA and filing acceptance by EMA for Kymriah

Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications


Merck’s KEYTRUDA receives China approval for Esophageal cancer
Drug Approval | September 09, 2021

Merck’s KEYTRUDA receives China approval for Esophageal cancer

The medicine is now approved for eight indications across five different types of cancer in China.